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Abstract 
Drug screening in urine is widely applied in forensic toxicology. Contrary to blood analysis, 
excessive or reduced fluid intake can substantially alter the concentration of substances in urine. 
As a standard to detect urinary dilution, creatinine concentrations are analyzed. A sample with a 
concentration below 20 mg/dL is generally defined as too diluted to provide a valid result in 
abstinence control samples. This work investigates the potential of three different methods for the 
determination of creatinine concentrations in urine samples: A ZIC-HILIC based LC-MS/MS 
method, a spectrophotometric method on an AU 480 chemistry system, and a portable, chemical 
reaction based, point-of-care testing device was compared by measuring 200 urine samples. When 
comparing the two laboratory methods, LC-MS/MS and spectrophotometry, a mean difference of 
3.7 ± 14 mg/dL was found, indicating that the spectrophotometric method is slightly overestimating 
the creatinine concentration. When comparing the LC-MS/MS method with the point-of-care 
testing device, a mean concentration difference within the calibration range for POCT (>20 mg/dL 
(excluding 16 samples) and <500 mg/dL (excluding 4 samples)) of 21 ± 37 mg/dL was found, 
indicating that the point-of-care testing device overestimates the measured creatinine 
concentration. A point-of-care testing device as used during this study can provide valuable 
information for on-site analysis. However, reported concentrations above 500 mg/dL should be 
further evaluated e.g. by dilution of the sample.  
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Introduction 
As excessive or reduced fluid intake can substantially alter the concentration of substances in urine, 
the necessity of investigating the urine’s dilution when measuring drugs of abuse (DOA) or 
performing ethyl glucuronide testing is widely known (1, 2). This is usually done by measuring 
creatinine, the internal anhydride of creatine (3). Based on a normal range of creatinine excretion 
from 14 to 26 mg/kg per day for men and 11 to 20 mg/kg per day for women, the urine’s creatinine 
concentration can vary massively, because the individual urinary creatinine output correlates better 
with muscle mass than with body weight (2). An obese person is thereby expected to have a lower 
urinary creatinine excretion than an athletic individual with the same or even lower body mass (3). 
Nevertheless, the measured urinary creatinine concentration is frequently used to provide 
information about the dilution, independent of the individual body composition of the donor: 
According to the European guidelines for workplace drug testing in urine, samples with a creatinine 
concentration below 22.6 mg/dL should be considered as dilute (4). Dilution of the urine may lead 
to an underestimation or non-detectability of the drug concentration (2). 
In this study, we provide a comparison between two laboratory methods for the urine’s creatinine 
analysis: liquid chromatography - mass spectrometry and spectrophotometry. In parallel, a point-
of-care testing (POCT) device based  on the oxidation of an indicator dye by a creatinine/copper 
complex and a hydroperoxide is evaluated by measuring the same urine samples as with the two 
laboratory methods. Knowledge about the reliability of such a portable device may help the 
investigator on-site, e.g. during roadside testing, to decide if an additional blood test, to detect drugs 
of abuse, is advisable. We refrained from testing the urine samples with an enzymatic assay using 
the Trinder Reaction, as various substances such as N-acetylcysteine (NAC), calcium dobesilate, 
acetaminophen and the metabolite N-acetyl-p-benzoquinone, metamizole and the metabolites 4-
aminoantipyridine (4-AAP) and 4-methylaminoantipyrine (4-MAP) cause falsified results for 
Trinder based assays (5-7). Acetaminophen and metamizole are often present in the studied 
population.  
Materials and methods 
Reagents 
Creatinine and creatinine-d3 were obtained from Sigma-Aldrich (St Louis, USA). Ammonium 
acetate fractopur® was ordered from Merck (Darmstadt, Germany). Acetonitrile (p.a.) was bought 
from Acros Organics (Geel, Belgium). Water was produced with a Milli-Q water system from 
Millipore (Billerica, USA). Creatinine reagent (Creatinine urine kit OSR 6178) for 
spectrophotometric calibration was obtained from Beckman Coulter (Nyon, Switzerland). A liquid 
assayed urine control for spectrometry (MAS Urichem Trak) was obtained from Thermo Fischer 
Scientific (Reinach, Switzerland). The P.I.A.2 POCT device and creatinine select plate tests were 
provided by Protzek (Lörrach, Germany). 
  
Study design 
89 urine samples used in this study were obtained from eight healthy volunteers participating in a 
drinking study (8). Further 111 samples reached the institute of forensic medicine for routine 
analysis (driving under the influence of drugs) and were analyzed for their creatinine concentration. 
The determination of the creatinine concentration by spectrophotometry represents a standard 
procedure which is generally performed for all urine samples sent to our laboratory. All samples 
were anonymized prior to analysis by using a specific sample identification code. In total 200 urine 
samples were analyzed for their creatinine concentration with three different methods: LC-MS/MS, 
spectrophotometry, and a chemical reaction based POCT device. 
Determination of creatinine by LC-MS/MS 
Sample preparation, analysis, and validation has recently been described in detail (8). Briefly, 50 
µL of urine and 150 µL acetonitrile containing the internal standard (creatinine-d3) were shaken for 
several minutes. After centrifugation, the supernatant was taken and evaporated to dryness. Prior 
to instrumental analysis, the sample was reconstituted in 400 µL of reconstitution buffer. 
Chromatographic separation was performed with a SeQuant® ZIC®-HILIC 3.5 µm, 100 Å, 150 x 
2.1 mm PEEK coated HPLC column (Merck, Darmstadt, Germany), heated at 30 °C, with a flow 
rate of 0.3 mL/min. Mobile phase A consisted of a 5 mM ammonium acetate buffer at pH 5.72 with 
0.1% formic acid, mobile phase B consisted of acetonitrile with 0.1% formic acid. The following 
14 min gradient was used: 0 to 1 min, 95% B;1 to 4.5 min, 95% to 20% B linear; 4.5 to 9 min, 20% 
B; 9 to 10 min 20% to 95% B linear; 10 to 14 min, 95% B. Mass spectrometric detection was 
performed on a Sciex 5500 QTrap system, operated in electrospray negative SRM mode (monitored 
transitions for crea: quantifier: 11268, qualifier: 11241, internal standard signal crea-d3: 
11542). Creatinine eluted from the column with a retention time of 5 minutes. Calibration was 
performed with a five point calibration prepared in solvent (2, 10, 30, 60, and 250 mg/dL), using a 
linear calibration model with weighting 1/x2. The correlation coefficient (R2) from least square 
regression were at least 0.9990. Four quality control samples (2, 10, 20, and 130 mg/dL) were used 
in each run. Samples with concentrations above the highest calibrator were reinjected after dilution. 
Mean intra-assay accuracy by measuring six samples of each quality control was 98.8-101.7%, and 
mean imprecision was 0.7-2.4%. Mean inter-assay accuracy from three series (n=3) with six 
samples of each quality control in each series was 98.9-101.4%, and mean imprecision was 0.6-
2.5%. Furthermore, extraction efficiency was determined to be 55 ± 13 %, the recovery was 53 ± 
11 %, and the matrix effects were 96 ± 12 %. The extracted quality control samples proved to be 
stable after storage for 72 h in the autosampler, after three freeze thaw cycles, and after storage for 
7 days at 4 °C. 
 
Determination of creatinine by spectrophotometry 
Spectrophotometric determination of creatinine was performed on a Beckman Coulter AU 480 
(Nyon, Switzerland). The colorimetric method is based on a kinetic test (Jaffe-reaction), whereby 
creatinine forms a complex with picric acid, as the deviation in absorption at 520/800 nm is 
proportional to the creatinine concentration within the sample (9, 10). The determination is based 
on a one-point calibration at 153 mg/dL, which is forced through zero. Commercially available 
quality control urine with a creatinine concentration of 57 mg/dL (acceptable deviation <20%) was 
included. According to manufacturer specification, the creatinine test shows linearity between 1 to 
400 mg/dL (10). A seven point linearity test (0, 10, 20, 50, 100, 200, 300, 400 mg/dL) in our 
laboratory revealed a correlation coefficient (R2) from least square regression of 0.9998. Based on 
repetitive measurements of the quality control sample during two months (n=17), mean imprecision 
was found to be 6.1%. 
Determination of creatinine by POCT 
POCT was performed on lateral flow, creatinine select plate tests with an automatic P.I.A2 readout 
system from Protzek (Lörrach, Germany), see figure 1. The test is a chemical reaction based device, 
using copper ions for complexation of the creatinine and a hydroperoxide for the oxidation of an 
indicator dye for color development of the test field. The calibration model for the determination 
of the creatinine concentration is based on a saturation curve by comparing the peak-volume 
(brightness of the reaction pad mounted on a lateral flow device) with the spiked concentration, 
which is established by measuring eight samples with different concentrations (0, 20, 40, 75, 125, 
200, 300, and 500 mg/dL) (figure 2). Accuracy measurements by comparing 24 human urine 
samples with spectrophotometric measurements revealed a mean accuracy of 112.5% and a 
correlation coefficient (R2) of 0.9453. Precision measurements during five days with a low (50 
mg/dL) and a high (100 mg/dL) creatinine concentration resulted in a mean imprecision of 10% 
and 5.7%, respectively. To investigate potential interferences, various substances such as glucose 
(100 mg/dL), uric acid (100 mg/dL), urea (3000 mg/dL), sodium chloride (1000 mg/dL), and 
proteins (BSA) (1000 mg/dL) were spiked to a 100 mg/dL creatinine stock solution in triplicate, 
whereby no influence on the test result was observed (mean imprecision <8%). For sample 
acquisition the following steps were performed: The provided buffer solution (400 μl, provided 
with the test cartridge) was mixed with 100 µL of urine, by using a Gilson Pipetman® 200M 
(systematic error ±1.00 μL, random error ≤0.26 μL). The mixture was shaken for ten seconds at 
1,500 rpm using a microtube shaker. Afterwards, 100 µL of the mixture were pipetted on the plate 
test and measured by automatic photometric readout on the P.I.A.2 system after three minutes. The 
result was provided in mg/dL of creatinine with a measurement window of 20 to 500 mg/dL. 
Alternatively, the device can be used in a direct interpretation mode, as shown in table 1 (11). Each 
sample was analyzed by a single measurement.  
 
Results and discussion 
LC-MS/MS vs. spectrophotometry 
When comparing the two laboratory methods, a Bland-Altman plot revealed a mean difference of 
-3.7 ± 14.3 mg/dL, indicating that the spectrophotometric method is overestimating the creatinine 
concentration, see figure 3. A one sample t-test reveals a P value of 1.61E-4, showing that the 
measured difference between the two methods is highly significant, which indicates the presence 
of a fixed bias. Linear regression analysis reveals a slope with y = 0.9732x + 6.85 and a R2 value 
of 0.9683, see figure 4. This results in an average systematic error of 3.7 mg/dL (y=0.9732x̅ + 6.85, 
whereby x̅ for the LC-MS/MS measurement equals 116.90 mg/dL) for the spectrophotometric 
measurement, which is in agreement with the previously mentioned mean difference of 3.7 ± 14.3 
mg/dL from the Bland-Altman plot. When comparing the LC-MS/MS results close to the cutoff 
concentration (30 mg/dL) for diluted urine, from 0 to 100 mg /dL (with respect to the LC-MS/MS 
result), linear regression analysis results in a slope of y=1.1484x – 2.80 and a R2 value of 0.9435, 
see figure 5. This indicates that the correlation coefficient between the two methods decreases as 
the observed relative concentration differences increase, when only low creatinine concentrations 
are investigated. A Bland-Altman plot revealed a mean difference of -5.0 ± 9.0 mg/dL for samples 
from 0 to 100 mg/dL. Reanalysis of ten randomly selected urine samples resulted in a mean 
difference of -10 ± 17 mg/dL for the LC-MS/MS analysis compared to -29 ± 13 mg/dL for the 
spectrophotometric analysis. Spiking of these ten urine samples with an additional 100 mg/dL of 
creatinine in order to investigate matrix effects resulted with an additional creatinine concentration 
of 105 ± 9 mg/dL for the LC-MS/MS measurement and 104 ± 11 mg/dL for the spectrophotometric 
measurement. 
When analyzing 20 urine samples in order to compare LC-MS/MS and the spectrophotometric 
method, the group of Derezinski et al. found a high correlation with a R2 value of 0.9844 between 
both methods. In 80% of the tested samples, the Jaffe method demonstrated an overestimation, by 
4.6% on average (12). Askenazi et al. found significantly lower urinary creatinine concentrations 
if samples were measured by the spectrophotometric Jaffe method compared to LC-MS/MS. The 
observed differences were however less than any clinically meaningful difference (13). A potential 
reason for this difference could be the preparation of calibration samples. It has to be mentioned, 
that a LC-MS/MS based method has less interfering substances and shows a higher specificity 
when it comes to creatinine analysis. This is mainly owed to the chromatographic separation of 
substances. On the other hand, numerous interferences such as acetone, cefazolin, glucose, 
bilirubin and lipids were found to influence the outcome of a spectrophotometric measurement 
(12). 
 
LC-MS/MS vs. POCT 
When comparing the LC-MS/MS method with the POCT device, a Bland-Altman plot within the 
calibration range for POCT (>20 mg/dL (excluding 16 samples) and <500 mg/dL (excluding 4)) 
revealed a mean difference of -20.7 ± 36.7 mg/dL creatinine, indicating that the POCT device is 
overestimating the creatinine concentration, see figure 6. With outlier elimination (n=20, <20 and 
>500), one sample t-test reveals a P value of 1.25E-12, showing that the measured difference 
between the two methods is significant, thus having a fixed bias. Linear regression analysis reveals 
a slope with y = 1.1513x + 1.80 and an R2 value of 0.8631, see figure 7. This reveals an average 
systematic error of 20.7 mg/dL (y=1.1513x̅ + 1.80, whereby x̅ for the LC-MS/MS measurement 
equals 124.61 mg/dL) for the POCT device, which is in agreement with the previously mentioned 
mean difference of 20.7 ± 36.7 mg/dL from the Bland-Altman plot. Based on the observed data, it 
is recommended to repeat measurements at the upper range of the scale (>500 mg/dL, n=4), as they 
proved to be invalid test results. Samples with a creatinine concentration <20 mg/dL (measured by 
POCT), accounting for dilute urine, were reliable in 15 out of 16 cases. In one case the POCT 
device found a creatinine concentration below 20 mg/dL, whereas the LC-MS/MS determination 
revealed a concentration of 41 mg/dL. Based on literature research, a direct comparison with 
another portable device for the determination of creatinine in urine is not possible. The currently 
available POCT devices for creatinine analysis such as the i-STAT (Abbott Point-of-Care, UK) 
and the Reflotron Plus (Roche Diagnostics, Switzerland) are intended to measure creatinine in 
whole blood, serum or plasma (14). Based on a review article by Mark DS Shephard, currently 
available POCT devices for creatinine measurements in blood can be divided into two types: blood 
gas analyzers such as the i-STAT and “non blood gas” analyzers such as the Reflotron Plus (15). 
  
Conclusion 
The observed differences between the three methods can be seen as significant (based on the one 
sample t-test). As expected, the two laboratory methods  LC-MS/MS and spectrophotometry are 
reliable and provide creatinine concentrations close to each other. LC-MS/MS measurements 
showed the highest reproducibility. Depending on the liquid chromatography used, creatinine 
determination can be implemented, within-run, in an already existing LC-MS/MS method for 
drugs-of-abuse testing. When comparing the POCT device with the LC-MS/MS method, 
differences in creatinine concentration are more distinct. However, with respect to diluted urine, 
15 out of 16 samples with a creatinine concentration below 20 mg/mL (measured by POCT) were 
identified correctly. It was therefore found that the POCT device may provide a useful tool for the 
on-site testing of creatinine concentrations. Especially the fact that the device interprets the test 
outcome automatically was appreciated. However, particular attention has to be paid when 
creatinine values above 500 mg/dL are reported (4 out of 200 samples, which represents 2%). In 
this case, a repetition of the measurement is recommended. 
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Tab. 1 Direct interpretation of creatinine results based on the P.I.A.2 device. 
Creatinine 
[mg/dL] 
Category Interpretation 
<20 Invalid Creatinine concentration is too low. Measurement has to be repeated at a different time point. 
20-50 Low The sample is diluted. Actual drug concentration might be higher 
50-150 Normal Creatinine concentration in normal range 
150-500 High Urine is concentrated. Actual drug concentration might be lower 
>500 Very high Very concentrated sample. Actual drug concentration might be much lower. 
  
Figure caption: 
 
Figure 1 Automatic P.I.A.2 readout system from Protzek with a creatinine test cartridge, a 
microtube, and a 100 μL pipette for the dilution of the urine. 
 Figure 2 Calibration curve for the POCT device based on a saturation curve established by 
comparing the peak volume (brightness of the pad) with the spiked creatinine concentration within 
the sample. (This figure was provided by courtesy of Protzek GmbH) 
Figure 3 Bland-Altman plot: S(x,y)= ((0.5×(S1+S2), S1-S2)), whereby S1 is represented by the 
LC-MS/MS concentration and S2 by the spectrophotometric AU 480 analyzer concentration. 
 
Figure 4 Comparison plot between the spectrophotometric method and the LC-MS/MS method. 
Linear regression reveals a correlation coefficient R2 of 0.9683 with y = 0.9732x + 6.85 
 
Figure 5 Comparison plot between the spectrophotometric method and the LC-MS/MS method 
from 0 to 100 mg/dL. Linear regression reveals a correlation coefficient R2 of 0.9435 with 
y=1.1484x - 2.80 
 
Figure 6 Bland-Altman plot: S(x,y)= ((S1,S1-S2)), whereby S1 is represented by the LC-MS/MS 
concentration and S2 by the concentration determined by the POCT device. Samples are presented 
within the calibration range for POCT (>20 mg/dL (excluding 16 samples) and <500 mg/dL 
(excluding 4 samples)) 
 
Figure 7 Comparison plot between the POCT device and the LC-MS/MS method. Linear regression 
reveals a correlation coefficient R2 of 0.8631 with y = 1.1513x + 1.80. Samples are presented within 
the calibration range for POCT (>20 mg/dL (excluding 16 samples) and <500 mg/dL (excluding 4 
samples)) 
